



**Figure 1.** Light scatter properties of analyzed cells (top). The flow cytometric dot plots clearly show that virtually all CD19<sup>+</sup> cells are positive for CD5 antigen and there are two cell populations with different HLA-DR antigen expression pattern. CD33 antigen is found to be the only antigen that expressed more than 50% of the cells and most of them are negative for HLA-DR antigen.

nosis but we do not have any doubts about the diagnosis because more than  $10 \times 10^9/L$  cells expressed CD5, CD19, CD20 and CD22 (Figure 1).

The concomitant presentation of AML and CLL is extremely rare and the use of two-color flow cytometry to differentiate the cell populations demonstrates the utility of this technology in the diagnosis of unusual hematologic malignancies.

Mustafa Nuri Yenerel, \* Ibrahim Hatemi, ° Hüseyin Keskin\*

\*Istanbul University, Istanbul Medical School, Department of Internal Medicine, Division of Hematology, Çapa, Istanbul; °Haseki State Hospital, Haseki, Istanbul, Turkey

### Key words

CCL, AML, flow cytometry.

### Correspondence

Mustafa Nuri Yenerel, MD, Istanbul University, Istanbul Medical School, Department of Internal Medicine, Division of Hematology, Çapa, Istanbul, Turkey. Fax: international +90.212.6311263.

### References

- Caballero MD, Gonzalez M, Canizo MC, Orfao A, Nieto MJ, San-Miguel JF. Concomitant chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Complete remission of CLL achieved with high-dose cytosine arabinoside. *Leukemia* 1992; 6:856-8.
- Conlan MG, Mosher DF. Concomitant chronic lymphocytic leukemia, acute myeloid leukemia, and thrombosis with protein C deficiency. Case report and review of the literature. *Cancer* 1989; 63:1398-401.
- Rai KR, Patel DV. Chronic lymphocytic leukemia. In Hoffman R, Benz EJ, Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE (eds): *Hematology: Basic Principles and Clinical Practice*. 2nd ed. Churchill Livingstone, New York, 1995, p 1308.
- Lima M, Porto B, Rodrigues M, et al. Cytogenetic findings in a patient presenting simultaneously with chronic lymphocytic leukemia and acute myeloid leukemia. *Cancer-Genet Cytogenet* 1996; 87:38-40.
- Mateu R, Bellido M, Sureda A, et al. Concomitant chronic lymphocytic leukemia and acute myeloid leukemia with an uncommon immunophenotype. *Am J Hematol* 1997; 56:281.
- Tamul KR, Meyers DC, Bentley SA, Folds JD. Two color flow cytometric analysis of concomitant acute myeloid leukemia and chronic lymphocytic leukemia. *Cytometry* 1994; 18:30-4.

### Acute megaloblastic anemia: homocysteine levels are useful for diagnosis and follow-up

Sir,

Vitamin B<sub>12</sub> (cobalamin) and folic acid deficiencies lead to megaloblastic anemia (MA), and induce accumulation of methylmalonic acid (MMA) and homocysteine (HCY).<sup>1</sup> The most common presentation of MA is classical macrocytic anemia. Other presentations are acute megaloblastosis (AM) and masked megaloblastosis.<sup>2,3</sup> In this report, we present a case of AM diagnosed and followed up by evaluation of HCY levels.

A 45-year old male was diagnosed as having Philadelphia-positive chronic myelogenous leukemia. Three years after diagnosis the patient developed a lymphoid blast crisis and was started on a chemotherapy protocol. The first consolidation treatment consisted of 6-mercaptopurine, methotrexate (MTX), VM-26 and cytarabine. MTX rescue with folinic acid was performed following standard guidelines. On day +14 a platelet count of  $9 \times 10^9/L$  was found. Hb was 99 g/L, mean corpuscular volume (MCV) 92 fL and leukocyte count was  $7.06 \times 10^9/L$  with 84% of neutrophils with hypersegmentation. Reticulocyte count was  $0.053 \times 10^{12}/L$  (1.66%). Vitamin B<sub>12</sub> levels and red cell folate were 322 pmol/L (normal 150-1200) and 938 nmol/L (normal 441-1285), respectively. A BM aspirate revealed 30% of erythroid precursors with megaloblastic features and a 55% of myeloid precursors with increased size and no blast cells. Serum HCY levels were 38  $\mu\text{mol}/L$  (normal < 16). The

**Table 1. Evolution of analytical parameters during folic acid and vitamin B<sub>12</sub> treatment.**

	Pre-treatment Day -9	Onset Day 0	Post-treatment Day +9
Platelets (x10 <sup>9</sup> /L)	134	9	112
Leukocytes (x10 <sup>9</sup> /L)	6.76	7.06	5.72
Hemoglobin (g/L)	91	99	95
MCV (fL)	93	92	95.3
Reticulocytes (x10 <sup>12</sup> /L)	0.037	0.053	0.163
Homocysteine (μmol/L)	-	38	9

AM, acute megaloblastosis; MCV, mean corpuscular volume.

patient was diagnosed as having AM and began treatment with folic acid 12 mg iv in one single dose and folic acid 5 mg/day po for 14 days and parenteral vitamin B<sub>12</sub> 2 mg/day for 4 consecutive days. After 10 days of treatment the platelet count increased to 112×10<sup>9</sup>/L and reticulocyte count to 0.163×10<sup>12</sup>/L (5.41%). Vitamin B<sub>12</sub> level was 716 pmol/L, red cell folate level 1,506 nmol/L and serum HCY level decreased to normal value (9 μmol/L) (Table 1).

Four different clinical forms of megaloblastosis have been described.<sup>3,4</sup> The classical form has an insidious onset with frequent neurologic symptoms and macrocytic anemia. Vitamin B<sub>12</sub> and/or red cell folate levels are decreased. The second form is the subtle MA anemia with ill-defined clinical symptoms and decreased or borderline vitamin B<sub>12</sub> and folic acid levels with other abnormalities (dUST, HCY, MMA).<sup>2</sup> Masked megaloblastosis coexists with other deficiencies; MCV is normal or decreased.<sup>5,6</sup> MA of acute onset is the rarest form.<sup>3</sup> There are two clinical presentations; the masked undiagnosed classical MA with cytopenias of abrupt onset and the so-called AM.<sup>3-7</sup> In AM severe thrombocytopenia develops in 1 to 3 weeks, MCV is normal or only moderately increased. This presentation is more frequent in patients with risk factors: parenteral nutrition, infection, dialysis or treatment with some antifolate drugs. Mortality is high.<sup>3</sup> The reticulocyte count is low. Vitamin B<sub>12</sub> and red cell folate levels are normal. BM aspirate shows megaloblastic changes. Classically, dUST is used as a diagnostic test. Nevertheless, HCY serum assays provide a sensitive test for the diagnosis of AM, especially in its early stages.<sup>8</sup> In vitamin B<sub>12</sub> deficiencies both HCY and MMA levels are high. In

folate deficiencies only HCY concentration is increased.<sup>9,10</sup> HCY levels are also useful for AM follow-up of AM; levels return to normal after starting treatment with vitamin B<sub>12</sub> or folic acid. The evaluation of serum HCY levels is an easy and non-invasive test for the diagnosis and follow-up of AM.

Marina Carrasco, Angel Remacha, Anna Sureda,  
Pilar Sardà, Rodrigo Martino, Jorge Sierra.

Department of Hematology, Hospital de la Santa Creu i Sant Pau,  
Barcelona, Spain.

### Key words

Acute megaloblastosis, folic acid, cobalamin, homocysteine

### Correspondence

Angel Remacha Sevilla, MD, Laboratorio de Hematología,  
Hospital de la Santa Creu i Sant Pau, Antoni Maria i Claret,  
167, 08025 Barcelona, Spain. Phone: international +34-93-2919290 – Fax: international +34-93-2919192 – E-mail: 2107@hsp.santpau.es

### References

- Green R. Metabolite assay in cobalamin and folate deficiency. *Baillière Clin Haematol* 1995; 8:533-66.
- Carmel R. Subtle cobalamin deficiency. *Ann Intern Med* 1996; 124:338-40.
- Remacha A, Gimferrer E. Las megaloblastosis agudas: revisión y reconsideración conceptual de las distintas formas de presentación de las megaloblastosis. *Biol Clin Hematol* 1984; 6:167-82.
- Carmel R. Pernicious anemia. The expected findings of very low serum cobalamin levels, anemia, and macrocytosis are often lacking. *Arch Intern Med* 1988; 148:1712-4.
- Spivak JL. Masked megaloblastic anemia. *Arch Intern Med* 1982; 142:2111-4.
- Bennett M, Koren A, Ludacer E. B12 deficiency in α-thalassemia. *N Engl J Med* 1984; 310:1058-9.
- Martinez E, Remacha A, Roca-Cusachs A. Acute exacerbation of folate-dependent chronic megaloblastosis. *Biol Clin Hematol*. 1992; 14:223-9.
- Vester B, Rasmussen K. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. *Eur J Clin Chem Clin Biochem*. 1991; 29:549-54.
- Allen RH, Stabler SP, Savage DG, Lindenbaum J. Diagnosis of cobalamin deficiency: I: usefulness of serum methylmalonic acid and total homocysteine concentrations. *Am J Hematol* 1990; 34: 90-8
- Lindenbaum J, Savage DG, Stabler SP, Allen RH. Diagnosis of cobalamin deficiency: II: relative sensitivities of serum cobalamin, methylmalonic acid and total homocysteine concentrations. *Am J Hematol* 1990; 34:99-107.